Stockreport

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for ...

PROVECTUS BIOPHARMS  (PVCT) 
NASDAQ:AMEX Investor Relations: provectusbio.com/financial-overview
PDF the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the University of Calgary's [Read more]